Axonics acquires technology to facilitate easier and faster placement of implantable leads for sacral neuromodulation

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from radian, llc that complements axonics' existing sacral neuromodulation (snm) offering. physicians determine a patient's eligibility for long-term snm therapy by performing an external trial or peripheral nerve evaluation (pne). t.
AXNX Ratings Summary
AXNX Quant Ranking